Neumora Therapeutics (NMRA) Stock Forecast, Price Target & Predictions
NMRA Stock Forecast
Neumora Therapeutics stock forecast is as follows: an average price target of $24.50 (represents a 148.48% upside from NMRA’s last price of $9.86) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
NMRA Price Target
The average price target for Neumora Therapeutics (NMRA) is $24.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $20.00. This represents a potential 148.48% upside from NMRA's last price of $9.86.
NMRA Analyst Ratings
According to 4 Wall Street analysts, Neumora Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for NMRA stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Neumora Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 22, 2024 | Ami Fadia | Needham | $23.00 | $11.28 | 103.90% | 133.27% |
| Jul 08, 2024 | Graig Suvannavejh | Mizuho Securities | $20.00 | $10.25 | 95.12% | 102.84% |
| Jun 17, 2024 | Brian Abrahams | RBC Capital | $29.00 | $9.71 | 198.66% | 194.12% |
| Mar 13, 2024 | Brian Abrahams | RBC Capital | $31.00 | $14.81 | 109.32% | 214.40% |
| Oct 10, 2023 | Brian Abrahams | RBC Capital | $24.00 | $10.91 | 119.98% | 143.41% |
| Oct 10, 2023 | Paul Matteis | Stifel Nicolaus | $26.00 | $10.91 | 138.31% | 163.69% |
The latest Neumora Therapeutics stock forecast, released on Jul 22, 2024 by Ami Fadia from Needham, set a price target of $23.00, which represents a 103.90% increase from the stock price at the time of the forecast ($11.28), and a 133.27% increase from NMRA last price ($9.86).
Neumora Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $25.75 |
| Last Closing Price | $9.86 | $9.86 | $9.86 |
| Upside/Downside | -100.00% | -100.00% | 161.16% |
In the current month, the average price target of Neumora Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Neumora Therapeutics's last price of $9.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jul 22, 2024 | Needham | - | Buy | Initialise |
| Jun 17, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Oct 10, 2023 | RBC Capital | - | Outperform | Initialise |
| Oct 10, 2023 | William Blair | - | Outperform | Initialise |
Neumora Therapeutics's last stock rating was published by H.C. Wainwright on Oct 01, 2024. The company Initialise its NMRA rating from "null" to "Buy".
Neumora Therapeutics Financial Forecast
Neumora Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Neumora Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. NMRA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Neumora Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict NMRA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Neumora Therapeutics's previous annual EBITDA (undefined) of $NaN.
Neumora Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-68.22M | $-69.81M | $-71.01M | $-71.81M | $-67.69M | $-62.32M | $-59.14M |
| High Forecast | $-68.22M | $-69.81M | $-71.01M | $-66.91M | $-60.17M | $-62.32M | $-59.14M |
| Low Forecast | $-68.22M | $-69.81M | $-71.01M | $-76.70M | $-69.20M | $-62.32M | $-59.14M |
| Surprise % | - | - | - | - | - | - | - |
Neumora Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. NMRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Neumora Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Neumora Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to NMRA last annual SG&A of $NaN (undefined).
Neumora Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.43 | $-0.44 | $-0.45 | $-0.45 | $-0.42 | $-0.39 | $-0.37 |
| High Forecast | $-0.43 | $-0.44 | $-0.45 | $-0.42 | $-0.38 | $-0.39 | $-0.37 |
| Low Forecast | $-0.43 | $-0.44 | $-0.45 | $-0.48 | $-0.43 | $-0.39 | $-0.37 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Neumora Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to NMRA previous annual EPS of $NaN (undefined).